Team:NEFU China/Human Practices

loading...
Top

Visit to a biopharmaceutical factory

Purpose

In order to further strengthen the connection between our project and the actual production, improve and optimize the project according to the requirements of the actual production, and explore the possible practical application directions and methods in the future, we visited a biopharmaceutical factory.

Place

Harbin Pharmaceutical Group Biological Co. LTD

Workshop Visit

Many thanks to the Harbin Pharmaceutical Group Biological Co., ltd. for accepting our application of visiting. Under the guidance of the staff, we visited the aseptic workshop of biopharmaceutical production and got to know the actual production process of biopharmaceutical drugs

Problem Consultation and Discussion

After the visit, we discussed the practical production possibilities of the project with the biological research experts of Harbin Pharmaceutical Group Biological Co., ltd. First of all, we knew that safety is the most important guarantee of biopharmaceuticals. At present, the production direction of microbial pharmaceuticals is mainly to produce a large number of targeting drugs through the fermentation and culture of engineering bacteria, and then conduct sterilization and purification treatment of the products. Finally, the produced drugs need to undergo strict aseptic testing and ingredient verification to ensure their safety. In the design of our project, bacteria will be used at the end, and thus non-specific sterilization treatment cannot be applied. Therefore, we need to consider how to avoid the contamination of miscellaneous bacteria and how to ensure the purity of the engineered bacteria produced at the final step. On the other hand, we discussed how the final product should be preserved if put into production. As suggested by the researchers, we felt that “freeze-dry” procedure should be used for the final preservation of the engineered bacteria. Thus, after the production is completed, the bacteria will be stored in the frozen-dried form. When the bacteria need to be used, the frozen-dried bacteria will be dissolved in physiological buffer for injection. The frozen-drying method has a good effect in preserving thallus, and the preservation time is considerably long. Next, we discussed other possibilities of product form with the researchers. They described a way to embed the engineered bacteria in a soluble membrane and inject it into the body as small particles. Embedding particles can increase the stability of bacteria, and precisely control the size, thereby reducing phagocytosis by macrophages. We think this is an interesting direction. Finally, we discuss the intravenous injection that holds many safety problems. The researchers proposed intratumoral injection, to reduce the engineered bacteria entering the blood circulation causing a series of problems. We fully agreed with their suggestion, and took this as a necessary process for the project if it can be clinically used in future.

Finally, we would like to thank Harbin Pharmaceutical Biological Company again for their strong support, and their scientific research staffs who answered our questions and gave us valuable suggestions!

Project Improvement & Outlook

For a long time finding a suitable agent to suppress bacteria in the healthy tissue is nowhere to be found since the environment in the body is changeable. Therefore, we went to visit the Professor Liu, hoping that he can give us valuable advice. Fortunately, we find a good way to suppress the bacteria in the healthy tissues.

The bacterium engineered to express CD convert the nontoxic nucleoside analog with antifungal activities 5-FC into a highly cytotoxic chemical, 5-fluorouracil (5-FU), which is a common anticancer drug. As a result, bacterium transformed with the CD gene expression cassette can be infected by 5-FC, eventually leading to their growth arrest and death.

At the suggestion of Dr. Yunfei Wang, we consulted the literature and visited the pharmaceutical factory to learn more about drug doses related to killing tumors, and the safety of living organisms. (TNF is a naturally occurring cytokine product of activated macrophages. The anti-tumor properties of TNF and its unique efficacy in selective destruction of tumor-associated vessels are well known.)

Therefore, we not only verified the agent effect of TNF, but also calibrate the dose of TNF produced by bacteria. What’s more, he encouraged us to reduce the harmful effects of bacterial metabolites.

As the result, the TNF-α is expressed after the induction, and TNF-α sample for 50% volume can kill 82.5% HepG2 cells, the TNF-α sample for 20% can kill 70.8% HeLa cells. Our system is able to induced by hypoxia and high lactic acid to secrete cytotoxic TNF-α, causing the evident death of HeLa and HepG2 cells.

Dr. Wang also gave us inspirations for the future works, and we hope to do some works on it.